-
Thursday, 10/31/2024
Aina García-Planchart, Internship Residence, Stucom Barcelona
Internship Residence, Stucom Barcelona
Internship Residence, Stucom Barcelona
Aina Garcia Planchart, a student in residence to obtain her Clinical and Biomedical Laboratory
Technician degree, is currently completing her professional training at IDIBAPS.From September 2024 to March 2025, she will support laboratory activities, assist researchers, and gain essential hands-on experience to prepare for her career in biomedical sciences.
-
Thursday, 10/31/2024
New fellow from Italy
Filippo Sartori, MD
Resident in a High-Dependency Unit at Verona University (Italy).
Staying at IDIBAPS from October 2024 until March 2025.
During his period at IDIBAPS, he will focus on critical care in respiratory medicine, especially on mechanical ventilation and the role of pronation in the outcome of ARF and ARDS. He will be involved in the ARDS-ECMO animal model experiment.
-
Monday, 10/28/2024
New ARISTOS’ fellow
Dr. Viviane Oliveira, from Brazil, staying in the research group from 2024 to 2027
Biologist, MSc. in Experimental Pathology, and Ph.D. in Science by the University of São Paulo / Brazil.
Dr. Viviane Oliveira has been awarded the prestigious ARISTOS fellowship. This esteemed grant, funded by the European Union's Horizon Europe research and innovation programme –under the Marie Sklodowska-Curie Actions (MSCA), is designed to support highly-qualified postdoctoral researchers with opportunities for international, intersectoral, and interdisciplinary research. Known for its highly competitive selection process, the ARISTOS grant provides not only financial support but also access to a vast network of research and training opportunities across CIBER and European institutions.With the ARISTOS fellowship, Dr. Oliveira will embark on a three-year research journey at our group focusing in define a safety protocol to apply Phages to treat Ventilator-Associated Pneumonia (VAP), namely on understanding biofilm growth on the surface of endotracheal tubes and efficiency of phage’s treatments, alone and in combination with antibiotics.
The project's impact reaches beyond the scientific realm, as its findings could aid in developing new treatments for VAP, enhancing patient outcome and tackling the issue of antibiotic resistance.
-
Monday, 09/16/2024
Prof. A. Torres Receives the ERS Lifetime Achievement Award in Respiratory Infections
Prof. A. Torres Receives the ERS Lifetime Achievement Award in Respiratory Infections
We are very honored as research fellows in Prof. Torres’ group to announce that last Saturday, he received the ERS Lifetime Achievement Award in Respiratory Infections, granted by the European Respiratory Society. For more information about this award, please follow the link: ERS Award Winners 2024.
-
Sunday, 09/01/2024
Lucia Alessandra Pasqua, fellow from Italy
Lucia Alessandra Pasqua, MD,
Resident in Anesthesiology and Intensive Care Medicine at University Magna Graecia of Catanzaro, Italy.
Staying in IDIBAPS from September 2024 to February 2025.
During her fellowship, she will be involved on research into respiratory diseases using animal models, with the goal of advancing our clinical understanding of these conditions and exploring new, evidence-based therapeutic approaches; also in studies on VAP (ventilator-associated-pneumonia).
This experience represents a significant opportunity for her, as it allows her to complement her clinical training with in-depth research work in an internationally renowned setting. Through this project, she is gaining specialized skills in experimental methodologies and translational research.
She is passionate about bridging the gap between research and patient care, aiming to bring scientific advancements from the lab to clinical practice to improve patient outcomes.
-
Friday, 08/16/2024
Launching of the HOMILUNG project website
Last June we launched the website of the Homi-Lung (www.homilung.com) a European project deciphering the causal relationship between cardiovascular and respiratory diseases progression and the immune and microbiome alterations observed during and after pneumonia. It has started in 2024 and it is expected to finish in 2029. Our research group IDIBAPS- Ciberes and Hospital Clinic (Lead by Prof. Antoni Torres) is mainly involved in WP2 (Prospective cohorts and patients need), WP6 (Causal link between pneumonia-induced dysbiosis and CVRD progression in preclinical models) and leads the WP7 (dissemination, communication, and exploitation).
-
Monday, 07/01/2024
Leticia Bueno Receives Nursing Award and Research Grant by the SEPAR (Spanish Society of Pulmonolgy and Thoracic Surgery)
Leticia Bueno has been awarded the 2nd Prize for Best Nursing Communications for the abstract titled "Association Between Malnutrition and Quality of Life in Patients with Bronchiectasis." In addition, she has received the Respira Grant for the Presentation of Communications at the National SEPAR Congress. This recognition highlights Leticia Bueno's significant contributions to nursing research and the impact of nutritional status on patients with bronchiectasis. -
Friday, 06/07/2024
ECCMID CONGRESS 2024, 27-30 April, Barcelona
Our research group has a
-
Friday, 02/02/2024
Ana Motos Awarded the Prestigious RESPIRE - MSCA Fellowship
Dr. Ana Motos, a promising researcher trained in our group in the field of respiratory infections, has been awarded the prestigious RESPIRE - Marie Skłodowska-Curie Actions (MSCA) fellowship. This esteemed grant, funded by the European Respiratory Society and the European Commission, is designed to support groundbreaking research and innovation. Known for its highly competitive selection process, the RESPIRE - MSCA grant provides not only financial support but also access to a vast network of research and training opportunities across Europe.
With the MSCA grant, Dr. Motos will embark on a two-year research journey at the University of Nantes under the supervision of Prof. Antoine Roquilly. Dr. Motos' project, titled "Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures," aims to define sub-phenotypes of respiratory microbiomes associated with the emergence of resistance during treatment and treatment failure. The project's implications extend beyond the scientific community, as findings may contribute to the development of targeted therapeutic approaches for pneumonia, improving patient outcomes, and addressing antibiotic resistance challenges.
-
Thursday, 02/01/2024
Kasra Kiarostami publishes Debut Paper as Lead Author
kasra Kiarostami wants to thanks to Prof. Antoni Torres, Dr. Laia Fernandez, Dr. Ana Motos and all collaborators in the Theravance project the recent article " The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia" was published in International Journal of Antimicrobial Agents journal. The first author is kasra Kiarostami.
In summary, this research compared the efficacy of telavancin and linezolid in addressing biofilms on endotracheal tubes (ETT) in a porcine model simulating methicillin-resistant Staphylococcus aureus (MRSA) ventilator-associated pneumonia (VAP). While MRSA loads on the ETT and cuff did not significantly differ among control, linezolid, and telavancin groups, a notable finding revealed telavancin's ability to reduce MRSA biofilm on the ETT. This suggests potential advantages for telavancin in clinical settings, especially for elective patients. Despite acknowledging the study's limitation of a small sample size, we argue that this model aligns with real-world VAP scenarios in critically ill patients, emphasizing the need for further investigation. The study highlights telavancin's potential significance in combating biofilms and improving treatment approaches for VAP."
Thank you!
